Reflection paper on the dissolution specification for ...
Reflection paper on the dissolution specification for generic solid oral immediate release productswith ... have an impact on the bioavailability. Ideally all non-bioequivalent batches should be detected by the : ... attributes may be particle size of the active substance or other attr ibutes that would have an impact on the . in vivo.
Download Reflection paper on the dissolution specification for ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Importance, Objectives & Factors Affecting Dissolution ...
pharmaquest.weebly.com3) PARTICLE SIZE There is a direct relationship between surface area of drug and its dissolution rate. Since, surface area increases with decrease in particle size, higher dissolution rates may be achieved through reduction of particle size.
2020 DOE Hydrogen and Fuel Cells Program Review ... - Energy
www.hydrogen.energy.govimpact on fuel economy Accept >10% power degradation over system lifetime No/limited hardware impact Approach: redefine “durability” System will provide <90% rated power in later years of lifetime No Easy to postulate, but really supplier decision. Hybridization Increase in battery size. Decrease in fuel economy.
General guidance on hold‑time studies
www.who.intblend uniformity, particle size, bulk/tapped density Initial, 15th day, 30th day, 45th day Core tablets – uncoated (in bulk container) Description, hardness, thickness, friability, disintegration, dissolution or dissolution profile, assay, degradation products/ related substance, uniformity of dosage units, microbial test Initial, 30th day,
Q12 Step 5 Technical and regulatory considerations for ...
www.ema.europa.eu− EC: The impact of particle size distribution (PSD) of API on blend homogeneity and dissolution could not be excluded during development. PSD was not studied outside the range of 20-50 um; this range is an EC. − Reporting: The impact of a change outside this range on blend homogeneity and
Discriminatory Dissolution Method Development and ...
dissolutiontech.comIn general, dissolution tests are useful for (1) assessing the characteristics of the active pharmaceutical ingredient (API) such as the particle size and the crystal form; (2) guiding development of new formulations; (3) assisting in proper formulation selection (selection of excipients) and optimizing the manufacturing process (e.g., compression